Skip to main
  1. Stocks
  2. Travere Therapeutics
  3. Forecast
TVTX

Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics (TVTX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Travere Therapeutics is benefiting from a powerful Filspari launch, with 3Q26 US net sales of $200.2M, up 120% year over year and 42% sequentially, while patient start forms of 1,932 still left room for further FSGS penetration as conversion to paid therapy improves. The company also looks well supported by a durable rare-disease franchise, with management guiding to more than $3B in total peak US sales by 2033 and recent patent allowance extending FSGS method-of-use protection into October 2037, which strengthens long-term exclusivity. Beyond the core product, a $471.8M cash position, a capital-efficient model, and pipeline catalysts for pegtibatinase in 2H27 and civorebrutinib by year-end 2026 add multiple avenues for upside.

Bears say

Travere Therapeutics is facing an unattractive risk-reward profile because valuation depends heavily on a narrow set of products and pipeline assets, while commercial, clinical, and regulatory setbacks across Thiola, Filspari, and development programs could materially impair prospects. The company reported $489.2M in cash, cash equivalents and marketable securities at the end of 1Q 2026 and $471.8M at the end of 3Q 2026, but that liquidity does not eliminate the need for additional capital if execution falters, leaving shareholders exposed to dilution from a follow-on stock offering. Any delays or disappointments in commercializing Filspari or pegtibatinase could reduce sales potential and undermine confidence in the company’s long-term valuation.

Travere Therapeutics (TVTX) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Travere Therapeutics (TVTX) Analyst Forecast & Price Prediction

Get the latest Travere Therapeutics (TVTX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Travere Therapeutics (TVTX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Travere Therapeutics (TVTX) Forecast

Analysts have given Travere Therapeutics (TVTX) a Buy based on their latest research and market trends.

According to 11 analysts, Travere Therapeutics (TVTX) has a Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Travere Therapeutics (TVTX)


Travere Therapeutics (TVTX) Analyst Forecast & Price Prediction

Get the latest Travere Therapeutics (TVTX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Travere Therapeutics (TVTX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover TVTX stock data and trends